期刊文献+

米力农与前列腺素E1防治心脏术后右心衰 被引量:7

Treating postoperative right ventricular failure by using milrinone and prostaglandin E1
原文传递
导出
摘要 目的静脉联合使用米力农(Mil)与前列腺素E1(PGE1)防治术后右心衰竭,并初步探讨其机制。方法选择体外循环下行心脏畸形矫正的先天性心脏病并肺动脉高压病儿28例,随机分为对照组(I组)、Mil组(II组)、PGE1组(III组)、Mil与PGE1合用组(IV组)。通过Swan-Ganz导管及动脉导管测定各组用药前后血流动力学指标,包括平均肺动脉压力(PAP)、平均主动脉压力(MAP)、心脏指数(CI)、体循环阻力(SVR)和肺循环阻力(PVR),并比较各组呼吸辅助时间及药物的毒副作用。结果与其他3组相比较,IV组用药后的PAP、PVR及SVR下降明显,同时CI显著增加,并缩短了呼吸辅助时间。结论静脉联合应用Mil和PGE1可有效防治术后右心衰的发生。 Objective To study the effect of milrinone(Mil) and prostaglandin E1 (PGE1) on postoperative right ventricular failure(RVF). Methods 28 patients with congenital heart diseases and pulmonary hypertension tmdergoing cardiopulmonary bypass (CPB) were randomly divided into four groups: control group (group Ⅰ), receiving Mil (Group Ⅱ), receiving PGE1 (Group Ⅲ), and receiving both Mil and PGE1 (group Ⅳ). The hemodyrmmic indexes of all the patients, including mean pulmonary artery, pressure (PAP), mean arterial blood pressure (MAP), cardiac index(CI), systemic vascular resistance (SVR) and pulmonary vascular resistance(PVR), were measured and compared. Intubation time and side effects were observed. Results Compared with the other three groups, postoperative PAP,PVR and SVR in group IV deceased and CI increased significantly. The intubation time was also shorter in group IV. Conclusion Postoperative RVF can be treated efficiently by using Mil and PGE1.
作者 祁家驹 于洋
出处 《中华胸心血管外科杂志》 CSCD 北大核心 2006年第5期308-310,共3页 Chinese Journal of Thoracic and Cardiovascular Surgery
基金 黑龙江省重大科技攻关项目资助(G98L19-2-1)
关键词 心脏缺损 先天性 心室功能障碍 手术后并发症 前列地尔 米力农 Heart defects, congenital Ventricular dysfunction, right Postoperative complications Alprostadil Milrinone
  • 相关文献

参考文献11

  • 1Brown KL,Ridout DA,Goldman AP,et al.Risk factors for long intensive care unit stay after cardiopulmonary bypass in children.Crit Care Med,2003,31:28-33.
  • 2Beyens T,Biarent D,Bouton JM,et al.Cardiac surgery with extracorporeal circulation in 23 infants weighing 2500 g or less:short and intermediate term outcome.Eur J Cardiothorac Surg,1998,14:165-172.
  • 3Haworth SG.Pulmonary hypertension in the young.Heart,2002,88:658-664.
  • 4Riedel B.The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery.Int Anesthesiol Clin,1999,37:55-79.
  • 5Hoffman TM,Wemovsky G,Atz AM,et al.Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.Circulation.2003,107:996-1002.
  • 6Felker GM,Benza RL,Chandler AB,et al.Heart failure etiology and response to milrinone in decompansated heart failure:results from the OPTIME-CHF study.J Am Coll Cardiol,2003,41:997-1003.
  • 7Zhang W,Ke H,Colman RW.Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.Mol Pharmacol.2002,62:514-520.
  • 8Mikawa K,Akamatsu H,Nishina K,et al.The effect of phosphodiesterase Ⅲ inhibitors on human neutrophil function.Crit Care Med.2000,28:1001-1005.
  • 9Tritapepe L,Voci P,Cogliati AA,et al.Suecessful weaning from cardiopulmonary bypass with central venous prostaglandin El and left atrial norepinephrine infusion in patients with acute pulmonary hypertension.Crit Care Med,1999,27:2180-2183.
  • 10de Perrot M,Fischer S,Liu M,et al.Prostaglandin El protects lung transplants from ischemia-reperfusion injury:a shift from pro-to anti-inflammatory cytokines.Transplantation,2001,72:1505-1512.

同被引文献64

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部